Inactive Instrument

Highlights Bausch Health Companies Inc Toronto S.E.

Equities

CA91911K1021

Highlights

Unlock all the news: Be the first to know and act before the market!

Bausch Health Sues Norwich for Patent Infringement Over Application for Generic Version of IBS Drug	06-21	MT
Bausch + Lomb Brief: To Present New Data at European Dry Eye Society 2024 Congress; Events Include Symposium on Patient-Centric Approaches to Dry Eye, "Highlighting Breakthroughs in Diagnosis, Treatment and Care"	06-17	MT
Bausch + Lomb Brief: Launching "Clinically Proven" Nutritional Supplement for Dry Eyes in the United States	06-03	MT
Bausch + Lomb Brief: Says Received Health Canada Approval for Full Visual Range Intraocular Lens	05-28	MT
Bausch Health Announces Wider Public Drug Plan Coverage for Uceris in Canada	05-23	MT
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024	05-17	CI
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich	05-15	MT
Bausch Health Down 6.6% In US After Hours As Updates Related to Norwich XIFAXAN Matters	05-14	MT
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters	05-14	MT
RBC Noes Bausch Health Filing For Rehearing in Appellate Court	05-13	MT
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform	05-03	MT
Bausch Health Shares Fall Following Q1 Results	05-02	MT
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance	05-02	MT
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance	05-02	MT
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis	05-02	MT
Bausch Health Companies Inc. Reaffirms Earnings Guidance for the Full Year 2024	05-02	CI
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
Needham Says Bausch + Lomb's Q1 Showed a "Strong Start" to The Year	05-01	MT
Bausch + Lomb Brief: Raising Full-Year 2024 Constant Currency Revenue Growth Guidance	05-01	MT
Bausch + Lomb Brief: Q1 Adjusted EBITDA (non-GAAP) of US$180 Million	05-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Bausch Health Companies Inc Toronto S.E.

Equities

CA91911K1021

Highlights

Filters